Glycoproteomics-based Liquid-biopsy LDT Development Service for Non Small Cell Lung Carcinoma (NSCLC)

Services Published Data

Glycoproteomics-based Liquid-biopsy for NSCLC

NSCLC is the most common type of lung cancer, which accounts for approximately 85% of all lung cancer cases. Glycosylation, as a post-translational modification (PTM) of proteins, has garnered significant attention due to its crucial role in diverse physiological processes and tumor development. Altered glycosylation patterns have been frequently observed on the cell surface and secreted proteins in lung cancer cells. Thus specific glycosylation patterns of proteins can serve as important biomarkers. Glycoproteomics-based liquid biopsy offers a non-invasive and highly informative method to identify and characterize glycosylation changes in cancer.

Glycoproteomics-based Liquid-biopsy LDT Development for NSCLC at Creative Biolabs

For glycoproteomic analysis of NSCLC samples, Creative Biolabs has established a robust and cutting-edge liquid-biopsy LDT platform with advanced techniques for the enrichment and analysis of glycopeptides to provide comprehensive information about glycan composition, branching patterns, glycosylation sites, and relative quantitation.

Fig.1 LDT development for N-glycosylation profiling in NSCLC samples.

Technologies for Glycoproteomics-based LDT Development at Creative Biolabs

By tailoring our approaches to specific needs, we adeptly select the most suitable method to enrich either targeted glycopeptides or global glycopeptides.
Additionally, we utilize multiple reaction monitoring (MRM) mass spectrometry for further validation of targeted proteins or peptides. MRM facilitates elevated specificity, enabling precise quantification with heightened sensitivity.

Fig.2 Technologies utilized for LDT development.

Advantages

Fig.3 Advantages of our LDT development.

Published data

Early detection of cancer and prediction of treatment response face major challenges. Liquid-biopsy technology, especially in glycoproteomics, has shown potential and can identify biomarkers non-invasively. Lung cancer is one of the leading causes of cancer death worldwide and is usually diagnosed in the late stages. Existing screening methods have problems such as high false positive rates. Studies have shown that glycoproteomics can effectively distinguish lung cancer patients from healthy controls, and some glycosylation markers change significantly in the early stages. These findings provide new possibilities for personalized treatment. However, this field still needs to further explore the specificity of glycosylation patterns, optimize detection technologies, and translate research results into clinical applications to improve the diagnosis and treatment of lung cancer patients.

Fig.4 Glycoproteomics analysis process for different diseases. Fig.4 LC-MS-based disease biomarker detection process.¹

Experienced scientists at Creative Biolabs are excited to leverage our specialized expertise to assist researchers worldwide in their pioneering projects focused on glycoproteomics-based liquid biopsy in NSCLC. Our offerings include top-notch custom services, tailored to accommodate our clients' specific requirements. To obtain more information, please feel free to contact us or submit an inquiry directly.

Reference

He, Kai, et al. "Decoding the glycoproteome: a new frontier for biomarker discovery in cancer." Journal of Hematology & Oncology 17.1 (2024): 12. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only.